

CapHiv

The CapHIV proposal addresses the need to increase the competitiveness of the SME partners by developing a cost-effective method to screen p24 capsid protein for the early diagnosis of HIV infection, a major health and economic threat to the quality of life of European citizens. A group of SMEs, covering the supply chain, have put together this proposal in order to gain the knowledge and resources to realise a CapHIV device exploiting the results of the novel, ultra-sensitive capacitance based sensor technology proposed by providing a fast and reliable early screening method in a cost efficient way.

The consortium guarantees complementary and synergistic business interests, ensuring a rapid and dynamic route of the technology to the market.



In this issue:

- Introduction
- Project progress
- Conferences
- Conference objectives
- Patents

Partners

Partner No.	Short name	Legal name	Country
1. (RTD)	MFKK	MFKK INVENTION AND RESEARCH CENTER SERVICES COMPANY LTD.	HU
2. (SME)	CAPSENZE	CAPSENZE HANDELSBOLAG	SE
3. (SME)	PHENO	PHENOSYSTEMS SA	CH
4. (SME)	LIO	LIONEX GMBH	DE
5. (SME)	ABBCN	AB BCN S.L.	ES
6. (SME)	FIMA	FIMA SRL	IT
7. (RTD)	LU	LUNDS UNIVERSITET	SE



Project progress

The project website (www.caphiv.eu) is operated and maintained regularly with news, public and confidential (partner access only) uploads. A questionnaire aimed at clinical laboratories, research facilities etc. was prepared to deal with clinical HIV diagnostics across Europe. The market assessment study is now complete and the answers were collected and processed into a market research analysis. The survey is still available on the project website: <http://www.caphiv.eu/survey>.

The CAPHIV concept has been successfully tested in laboratory setup, with several hundred samples. The advantage of the utilized technology is that it is able to work directly from whole blood. The detection time including sensor regeneration and cleaning is around 10 minutes, enabling a short sample to result time in point-of-care use. A durability of 100 detection cycles per sensor chip could be achieved by careful optimization of the regeneration and cleaning methodology, as well as the reduction of non-specific binding to a negligible level by surface chemistry optimization. The developed detection methodology enables a continuous self-calibration during the measurement process ensuring the result quality. These research works have been successfully completed.

The project is now focusing on hardware development to implement the technology as an easy to use, stand-alone screening device. A special disposable sensor cartridge and docking station concept has been developed with the aim to minimize the cost of the disposable sensor component (cartridge) without compromising detection performance. This is ensured by high precision positioning in the docking station and an innovative electrode needle solution ensuring reproducible measurement conditions, as well as by the development of a suitable calibration protocol. In parallel to the device development the project is preparing for the pre-clinical validations with modeled samples using isolates.

<http://www.caphiv.eu/survey>.

cap...
Rapid
Screening **HIV**

Conferences

11th European Meeting on HIV & Hepatitis

- City: Rome
- Country: Italy
- Dates: 20 - 22 March 2013
- Event Type: Conference
- Subject: treatment Strategies & Antiviral Drug Resistance



Conference objectives

This meeting was started 10 years ago with the objective to provide clinical virologists and other infectious diseases treating specialists involved in both research and clinical practice with the opportunity to share data and discuss their clinical application. The focus of the workshop at the time was specifically on HIV antiretroviral drug resistance, which was the main challenge facing the clinician a decade ago. Hence the original name as the European Drug Resistance workshop.

Over the years the challenges facing European clinicians treating HIV patients expanded. As resistance was better understood and managed, broader treatment issues (adherence, toxicity, etc.) were added to the workshop. Similarly, as better treatments for HCV became available, many of them were required to treat viral Hepatitis as well. Therefore the workshop (and its name) were expended to keep pace with the needs of the European clinicians – The European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance. Although resistance is still an important feature of the meeting, the other key topics in treatment strategies are addressed – similarly although HIV remains very much a key component – treatment of Hepatitis infection is also included. Of note, although the topic of HIV/Hepatitis co-infection is touched on if relevant to a specific issue – it is not the focus of the workshop nor a major topic during presentation and discussion.

By attending the 10th edition of this meeting, you will receive a full overview of the latest developments in Hepatitis B, C and HIV, translated to clinical practice. The meeting will provide ample time for Q & A, discussion and interaction in a balanced and neutral scientific environment. Furthermore, much attention will be given to clinical management through extensive clinical case discussions.

<http://www.virology-education.com/>



17th Cohorts Workshop

The conference will attract many health professionals from all over the world to Antalya with the slogan "STI and HIV: Time for protection"

City: Cavtat

Country: Croatia

Dates: 11/4/2013 - 13/04/2013

Event Type: Workshop



Workshop's mission

The objective of this conference is to bring together junior and senior researchers from both developed and developing countries working on cohorts of patients with HIV, to present in an informal, closed-meeting format their latest findings and work in progress and allow open discussions on common issues of cohort methodology, techniques and statistics. This conference aims at pursuing new findings or analyses and facilitating scientific debates of methods, results, and clinical and epidemiological implications of the HIV epidemic in Europe and elsewhere in the world. We are once again aiming to include attendees representing cohort studies from all regions. As in the past, we encourage discussion of work in progress, this thus is a closed meeting and all data presented will not be publicized outside of the workshop, this includes the program not being distributed prior to or after the meeting.

<http://www.hivcohorts.com/>



Patent Watch

List of Whole Blood, Serum or Plasma-based HIV Tests (sorted by producers)

Abbott Diagnostics: PRISM HIV O Plus and AxSYM® HIV 1/2 gO

Bio-Rad Laboratories: GS HIV-2 and GS HIV-1/HIV-2 PLUS O EIA

Green Cross: The Genedia HIV 1/2 ELISA 3.0 PLUS

Maxim Biomedical: The Serum/Plasma HIV-1 Microelisa System

Ortho-Clinical Diagnostics: VITROS HIV-1/HIV-2

Shanghai Kehua: Anti-HIV 1+2 Antibodies ELISA Diagnostics Kit

Siemens Healthcare Diagnostics:
ADVIA Centaur HIV 1/O/2 Assay and The Enzygnost Anti-HIV 1/2 Plus Assay

Span Diagnostics: Enzaids

Biomedical, Inc.: UBI HIV-1/2 EIA test



cap...
Rapid
Screening **HIV**

